Published in final edited form as:

Semin Nephrol. 2008 March ; 28(2): 143–151.

The Roles and Mechanisms of Intestinal Oxalate Transport in Oxalate Homeostasis

Marguerite Hatch and Robert W. Freel

Department of Pathology, Immunology & Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL 32610

Abstract

The mammalian intestine has an important role in the dynamics of oxalate exchange and thereby is significant in the etiology of calcium oxalate nephrolithiasis. Here we review some of the phenomenological observations that have led to the conclusion that anion exchangers (antiporters) are important mediators of secondarily active, net oxalate transport along the intestine (both absorptive and secretory). Understanding the mechanisms of transepithelial oxalate transport has been radically advanced in recent years by the identification of the SLC26 family of anion transporters which has facilitated the identification of specific proteins mediating individual apical or basolateral oxalate transport pathways. Moreover, identification of specific exchangers has underscored their relative importance to oxalate homeostasis as revealed by using knockout mouse models and facilitated studies of oxalate transport regulation in heterologous expression systems. Finally, the significance of oxalate degrading bacteria to oxalate homeostasis is considered from basic and applied perspectives.

Keywords

Absorption; Secretion; Anion Exchange; SLC26; *Oxalobacter sp.*

Introduction

Hyperoxaluria is considered to be a major risk factor in calcium oxalate nephrolithiasis which occurs in about 12% of the population (1). The importance of the intestine in this "renal disease" stems from three facts. First, since urinary oxalate is ultimately derived from dietary (net intestinal absorption) as well as endogenous (hepatic metabolism) avenues (2), intestinal oxalate absorptive mechanisms are significant. Second, while the principal route for oxalate excretion is through the kidneys, considerable intestinal excretion (net intestinal secretion) of oxalate occurs in some pathological conditions that has *adaptive* significance (3,4). Third, certain microorganisms resident in the mammalian gut can degrade oxalate (5–11), suggesting they can also potentially contribute to the mass balance of oxalate.

In this brief overview of the role of the intestine in oxalate homeostasis we consider some of the phenomenological aspects of intestinal oxalate transport (handling) that have led to the notion that the bulk of net transcellular oxalate transport, either absorption or secretion, occurs

Mailing Address: Marguerite Hatch, Ph.D., Department of Pathology, Immunology & Laboratory Medicine, P.O. Box 100275, 1600 S.W. Archer Road, Gainesville, FL 32610, Phone: (352) 392-0013, Fax: (352) 392-3053, e-mail: hatchma@ufl.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

via anion exchangers (antiporters). We then consider the emerging importance of gene families encoding these anion exchangers, especially SLC26, and how an understanding of these proteins and their segmental and cellular distribution, has led to a better understanding of intestinal oxalate exchange in health and disease. Finally, recent information on the role of oxalate degrading bacteria (*Oxalobacter*) in modulating intestinal oxalate handling will be considered. Previous reviews of oxalate handling in intestinal (10,12–14) and renal epithelia (15,16) may be consulted for additional perspectives (e.g., animal models simulating oxalate-associated disease states; factors influencing intestinal oxalate absorption).

Phenomenological Aspects of Intestinal Oxalate Transport

The transepithelial, unidirectional flux of any solute (mucosal to serosal or serosal to mucosal) is the sum of parallel flows through paracellular and transcellular pathways. Establishing the relative importance of these two avenues is fundamental to understanding oxalate handling *in vivo*, but no systematic study has been presented to quantitate their relative roles in secretion or absorption. Early models for oxalate absorption in the intestine favored a non-mediated, passive, gradient-driven flux through paracellular pathways (17). However, it later became apparent that an energy-dependent, net absorption of oxalate could be demonstrated using short-circuited rat distal colon in the absence of a transepithelial oxalate gradient and employing physiological concentrations of oxalate ($< 2 \mu\text{M}$) on both sides of the epithelium (18). The apparent active, transcellular absorption of oxalate we observed in the rat colon promoted a number of additional studies characterizing the segmental heterogeneity, ion dependencies, inhibitor profiles, and some regulatory aspects of oxalate transport in rat and rabbit intestine which are considered below.

Paracellular Exchange

Before considering the transcellular avenues in detail we should like to re-emphasize that *in vivo* the relative significance of paracellular (shunt) oxalate transport (in the secretory or absorptive direction) is only vaguely defined. As flow through this pathway is dependent upon the prevailing transepithelial electrochemical potential differences of the oxalate anion, it is anticipated that different segments will support different levels of passive oxalate transport. In this sense, it might be expected that along the early portions of the intestine - where junctional resistance is typically low and luminal oxalate activity is expected to be higher - that the shunt contributes significantly to oxalate absorption. In contrast, the contribution of paracellular pathways to oxalate absorption in more distal segments like the colon - where luminal oxalate activity might be lower and junctional resistance is much higher - is likely to be less.

The importance of paracellular oxalate absorption is best demonstrated in the pathology of Enteric Hyperoxaluria associated with the malabsorption of fatty acids and bile salts (17,19, 20). Normally, these luminal solutes are efficiently absorbed in the small intestine. However, in malabsorption syndromes (secondary to disease (21–24) or small bowel resection (25)) these secretagogues promote increases in the paracellular permeability of the large intestine (23, 26) leading to the passive hyperabsorption of oxalate in proportion to the luminal activity of the oxalate ion (20).

Transcellular Absorption

Apical Uptake While the initial studies with isolated rat distal colon clearly indicated net absorption of the oxalate ion in the absence of any electrochemical driving forces (18), the nature of this active oxalate absorption was not clear. The transcellular absorption of oxalate requires an uptake mechanism at the apical membrane followed by an efflux mechanism across the basolateral membrane of the epithelium. In the course of several studies employing isolated, short-circuited segments of rabbit distal colon it became apparent that net oxalate absorption

was an energy-dependant process exhibiting many characteristics that were concurrently emerging for active chloride absorption. For example, net oxalate absorption and sodium absorption were inhibited by 100 μ M DNP (2–4 dinitrophenol, an uncoupler of oxidative phosphorylation) confirming the energy-dependence of these active transport systems (27). Also in the rabbit distal colon the anion exchange inhibitor SITS (4-acetamido-4-isothiocyano-2,2'-stilbene-2,2'-disulfonic acid) applied mucosally (100 μ M) inhibited net chloride and oxalate absorption without affecting short-circuit current, primarily by reducing the M to S unidirectional fluxes (27). Furthermore, the carbonic anhydrase inhibitor acetazolamide significantly reduced net chloride and oxalate absorption in the nominal absence of HCO_3^- in the buffers. From these findings it was concluded that oxalate absorption was a secondarily active process that was likely mediated apically by an anion exchanger (antiporter) that was similar to that mediating chloride absorption. Somewhat later these notions regarding apical oxalate transport were confirmed and extended in studies employing brush border membrane vesicles (BBMVs) isolated from the rabbit distal ileum (28,29). From the latter studies it was predicted that there were at least three separate anion exchangers in rabbit BBMVs: a $\text{Cl}^-/\text{HCO}_3^-$ exchanger; a $\text{SO}_4^{2-}/\text{OH}^-$ exchanger, which also transports oxalate; and an $\text{Ox}^{2-}/\text{Cl}^-$ exchanger, all of which were reported to be electroneutral. Thus, twenty years ago there was strong empirical support for the notion that net transepithelial oxalate absorption was apically mediated by anion antiporters more commonly regarded as chloride/base exchangers - a fact that presaged current efforts to establish the roles of multifunctional anion exchangers in the SLC26 gene family to oxalate handling.

Basolateral Efflux Concomitant with the recognition of apical antiporters as mediating oxalate uptake in the intestine, was the empirical development of the idea that anion exchange may also account for oxalate efflux across the basolateral membrane of absorptive enterocytes. Thus, in rabbit distal colon serosal addition of 1 μ M DIDS (4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid) reduced net oxalate absorption by 43% without affecting net chloride absorption and serosal Na^+ removal decreased net oxalate absorption without affecting net Cl^- absorption (30). Additionally, net oxalate absorption (but not Cl^- absorption) exhibited a dependence on serosal (but not mucosal) Na^+ as judged by the effects of serosal amiloride (1 mM) and serosal Na^+ replacement (30). It was concluded that the mechanism(s) mediating oxalate efflux across the basolateral membrane during absorption was an anion exchanger (DIDS-sensitive) mechanistically distinct from that mediating apical uptake. The marked sodium-dependence was proposed to result from a coupling of base anion/oxalate exchange with pH regulation via a basolateral Na^+/H^+ exchanger (30).

Transcellular Secretion

Up to the early 1990s, it appeared that the mammalian intestine functioned only in an absorptive mode with respect to oxalate, but it is now clear that net enteric oxalate secretion/excretion also occurs which may have a significant impact on oxalate homeostasis. Studies using short-circuited tissue preparations from rabbits (30,31), rats (4,14), and more recently mice (32, 33), have indicated that oxalate handling along the mammalian intestinal tract varies in both magnitude and direction in a segment-specific manner. Invariably, under control conditions, the small intestine and proximal colon exhibit a net secretion of oxalate whereas the distal colon supports net oxalate absorption. Under certain conditions, following the addition of cAMP for example, the distal colon can support a net secretory flux of oxalate (30). We have proposed that such secretagogue-induced oxalate secretion across this segment is mediated by a furosemide-sensitive basolateral uptake process and passive diffusion of accumulated oxalate through an apical conductive pathway that can be partially blocked by the Cl^- channel blocker NPPB (30,34). We proposed that electrogenic oxalate flux in BBMVs (34) was mediated by an anion channel like CFTR, however we have recently observed that ^{14}C -oxalate efflux from *Xenopus* oocytes expressing human CFTR is the same as water injected oocytes (unpublished

observations). This indicates that oxalate secretion, at least in humans, may not be mediated by the CFTR chloride channel *per se*. Recent findings that some of the members of SLC26 are electrogenic (35) and functionally interact with the CFTR gene product in a regulatory manner (36,37) may be relevant in this regard.

The SLC26 Gene Family and Intestinal Oxalate Transport

Until recently, phenomenological approaches described above represented the sole experimental basis for our current understanding of intestinal oxalate handling. Unraveling mechanisms was difficult because it was not possible to identify specific transport proteins beyond anion selectivity and inhibitor profiles which often overlap. This has changed considerably with the identification of the SLC (solute-linked carrier) gene superfamily which encodes for proteins that mediate anion transport (38–40). Particularly relevant to the current discussion are several structurally related proteins encoded by the SLC26 gene family that are anion transporters having measurable affinity for oxalate and are expressed in the intestine (38–40). Oxalate transporting members of this family that are found in the GI tract are: SLC26A1 (SAT1), SLC26A2 (DTDST), SLC26A3 (DRA), SLC26A6 (PAT1 or CFEX), SLC26A7, and SLC26A9. SAT1 is located in the human small intestine and colon (41) and in post-confluent monolayers of Caco-2 cells, (42), presumably basolaterally (as in the proximal tubule (43)). DTDST is relatively abundant in the human large intestine and less in small intestine (44) and we have observed SLC26A2 mRNA in rat intestine (42) and in confluent Caco-2 monolayers (45). The affinity of DTDST (SLC26A2) for oxalate has not been clearly defined. In mice (46) and rats (47), DRA (SLC26A3) is abundant in the apical membrane of colonocytes and less so in the small intestine. In mice, PAT1 (slc26a6) is abundant in the apical membrane of the duodenum and ileum but less so in the colon (48,49). The isoforms SLC26A7, SLC26A9 have been detected in gastric mucosa (39); yet, while the stomach may mediate passive oxalic acid absorption by non-ionic diffusion (10), neither the mucosa nor the resident SLC26 transporters have been implicated in mediated oxalate flux.

Studies in Knockout Mice

The utility/importance of identifiable molecular entities is nowhere better demonstrated than with the use of targeted disruption of genes encoding oxalate transporters. For example, the examination of oxalate transport across the ileum of slc26a6 null mice made by Freel *et al.* (32) revealed that slc26a6 represents a major apical membrane pathway mediating oxalate efflux rather than influx under normal conditions (32). The wild-type (WT) mouse ileum supported a small net secretion of oxalate that was sensitive to the mucosal addition of DIDS (200 μ M) whereas in the PAT1 KO mice there was a significant net absorption of oxalate that was DIDS-insensitive. In addition, these KO mice were hyperoxaluric compared to the WT, presumably due to the enhanced net absorption of oxalate. This study also demonstrated that Cl^- is an exchange partner for oxalate efflux across the apical membrane of the mouse ileum and there was no evidence that PAT1 mediated oxalate efflux was regulated by intracellular cAMP. Using an independently generated slc26a6 null mouse model, Jiang *et al.* (33) also observed an increase in duodenal oxalate absorption in their PAT1 KO mouse model compared to WT. Interestingly, these KO mice had a high frequency of oxalate bladder stones, unlike the KO animals used by Freel *et al.* despite a similar degree of hyperoxaluria. This curious and important phenotypic difference between the PAT1 KO models may possibly be explained by the different background strains of the mice used in each study and/or the fact that the KO mice used by Jiang *et al.* were significantly hypercalciuric (urinary Ca^{2+} concentration = 6.73 mM $\pm$ 1.71, n = 10) compared to the PAT1 KO model used in our studies (1.49 mM $\pm$ 0.35, n = 5, unpublished observations). The study by Jiang *et al.* (33) also provided evidence to suggest that a large contribution of urinary oxalate in their PAT1 KO model was derived from dietary sources; however, they could not completely exclude some renal involvement. It is notable that

their results did show reductions in oxalate excretion and serum oxalate in the KO mice fed an oxalate-free diet, but, both were still significantly higher than in WT fed a similar diet. We would argue that since both intestinal and renal epithelia are the principal interfaces for exchange of oxalate, and since the PAT1 transporter is expressed in both epithelia, it is reasonable to assume that changes in urinary oxalate excretion result from oxalate transport activity at both of these interfaces.

Since PAT1 appears to mediate apical oxalate efflux (cell to lumen) in the mouse small intestine (32,33), we have speculated that DRA (slc26a3) (32) may mediate apical oxalate uptake (lumen to cell) in the intestine. If this is correct, we would expect that intestinal oxalate absorption should be reduced in DRA KO mice (50) compared to WT mice and urinary oxalate excretion would decrease in DRA KO mice. The following preliminary results (unpublished observations) we have obtained using DRA heterozygotes (HETS) as well as DRA KO mice were consistent with this expectation. In the HETS, significant reductions were observed in the mucosal to serosal flux of oxalate in both distal ileum (~ 23% decrease) and distal colon (~ 50% decrease), while urinary oxalate excretion was significantly reduced from 1.70 ± 0.23 $\mu\text{moles}/24 \text{ h}$ in WT compared to 0.87 ± 0.11 $\mu\text{moles}/24 \text{ h}$ in the HETS (n=9 in each group). In the small number (n=3) of DRA KO mice we have examined thus far, the mucosal to serosal flux of oxalate in the distal ileum was reduced 45% and urinary oxalate excretion was also lower and comparable to the HETS. Thus, in the absence of DRA, the mouse ileum supports a sizeable net secretory flux of oxalate (~ 9-fold greater than the WT) primarily due to decreases in the absorptive component of the flux. Since DRA is not present in the kidney (50,51), the reduced intestinal absorption of oxalate in these mice most likely contributes to the reduction in urinary oxalate excretion in slc26a3 null mice.

Regulation of Intestinal Oxalate Transport and SLC26 Isoforms

Functionally, it has been demonstrated that colonic oxalate secretion can serve as an extra-renal route for oxalate excretion both in rats with chronic renal failure (CRF) and in rats challenged by an oxalate load (4,52–54). The CRF-stimulated enteric secretion was correlated with a local up-regulation of angiotensin II (ANG II) receptors and was demonstrated to be mediated by serosal AT₁ receptor activation (52,53). These studies also provided evidence for hyperoxalemia-induced oxalate secretory pathways that are independent of ANG II regulation and distinct from those secretory pathways previously implicated (54), i.e. cAMP-induced secretion. Serosal epinephrine (50 μM) changes net oxalate transport across the isolated, short-circuited rabbit proximal colon from a secretory to an absorptive mode *via* increases in the mucosal to serosal oxalate flux and a decrease in the serosal to mucosal flux (31). These phenomenological studies clearly demonstrate that oxalate transport is affected by neurohormonal effectors - but transporters mediating these changes have not been resolved.

There is little presently known about the regulation of oxalate handling mediated by the SLC26 transporters in the intestine, but this is likely to change considerably. It is expected, however, that because most of these anion exchangers are involved with acid-base regulation of intestinal cells, oxalate flux will be affected to some extent by factors regulating intracellular pH (10). PAT1 is reported to be the principal $\text{Cl}^-/\text{HCO}_3^-$ exchanger in the apical membrane of the upper villous epithelium in mouse duodenum with a smaller contribution by DRA (48). One of the more novel aspects of HCO_3^- regulation (and possibly oxalate transport, directly or indirectly) is the suggested mechanism of acute regulation *via* disruption of bicarbonate transport metabolons. For example, it has been proposed (55) that SLC26A6 forms a transport metabolon by complexing with carbonic anhydrase II (CAII). Apparently, because the binding location for CAII on PAT1 is adjacent to the protein kinase C (PKC) phosphorylation site, PKC disruption of CAII binding results in reduced bicarbonate transport rates (55). The significance of this mechanism to SLC26A6 mediated intestinal oxalate transport is not certain, since

SLC26A6 exhibits multiple modes of anion exchange independent of HCO_3^- transport (38). In this regard, it has been reported (56) that phorbol ester activation of PKC reduces the serosal to mucosal flux of oxalate across the mouse duodenum by about 50%, an effect that was blocked by the PKC- δ inhibitor, rottlerin. Whether PKC altered net oxalate transport by mouse duodenum was not reported. In parallel studies of *Xenopus* oocytes expressing mouse slc26a6, PKC activation also reduced $\text{Cl}^-/\text{Ox}^{2-}$ exchange and this reduction was considered to be secondary to the endocytotic withdrawal of slc26a6 from the oocyte membrane (56).

The intriguing observations that the SLC26 transporters may interact with CFTR (36,50,57–59) or modify other transporters (47) afford another emerging regulatory aspect of these anion/base transporters. For example, CFTR upregulates SLC26A3 and SLC26A6 function in cultured pancreatic duct cells (60) and co-expression of DRA or PAT1 with CFTR in HEK293 cells (36,61) mutually activates their physiological functions (Cl^- -dependent pH changes and Cl^- current, respectively). In the latter study, it was proposed that the SLC26 transporters and CFTR exist in a complex by binding to scaffolds containing PDZ domains and interactions between the CFTR R-domain and the SLC26 STAS domain results in mutual activation of CFTR and the SLC26 transporters (36,57). Another indication that SLC26 proteins have a regulatory potential comes from a report that rat slc26a3 does not mediate significant DIDS-sensitive $\text{Cl}^-/\text{HCO}_3^-$ exchange when expressed in HEK293 (47). It was suggested that if this were true for human DRA, then mutations in slc26a3 (62) leading to congenital chloride diarrhea (low pH with high Cl^-) could not be solely due to defective DRA-mediated $\text{Cl}^-/\text{HCO}_3^-$ exchange *per se* (47). This would imply that slc26a3 may act as a modifier gene for other unidentified transporters (47).

Role of Oxalate-Degrading Bacteria

Several intestinal bacteria have been reported to degrade oxalate and these include *Eubacterium lentum* (5), *Enterococcus faecalis* (6), lactic acid bacteria *Lactobacillus sp.*, *Streptococcus thermophilus*, *Bifidobacterium infantis* (7,8), and *Oxalobacter sp.* (9,10). More recently, a novel oxalate-degrading member of the *Enterobacteriaceae* (*Providentia rettgeri*) was identified in human fecal samples and, notably, this organism was also reported to have enzymes similar to those of *Oxalobacter formigenes* (11). The major focus of the following section is on the role of the substrate/oxalate-specific *Oxalobacter sp.* in intestinal handling of oxalate simply because it has received the most attention in this regard by investigators. For earlier reviews of the oxalate degrading bacteria, see Allison *et al* (63), Goldfarb (64) and Hoppe *et al* (65). We also recommend the section on *Oxalobacter* in a previous review as background material for the present discussion (10).

Studies in Animals

Oxalobacter sp. has been found to be present in the intestines of most wild and domesticated animals that have been tested, however, it is not typically present in laboratory rats (10,63). The results of all of the studies examining the effects of *Oxalobacter* on oxalate handling in laboratory rats are consistent and it is generally concluded that urinary oxalate can be reduced by oral administration of encapsulated oxalate-degrading enzymes from *Oxalobacter* (66,67) or by administering viable whole *Oxalobacter* cells (68). Reasonably, this effect has been assumed to be due to degradation of dietary oxalate by the bacterial enzymes produced in the luminal compartment. Certainly, a favorable transepithelial gradient across the intestine will promote the passive movement of oxalate from the blood if luminal oxalate concentrations are maintained lower by *Oxalobacter* enzyme activity and this may be particularly important in severe hyperoxalemic conditions such as Primary Hyperoxaluria and Enteric Hyperoxaluria. We have proposed that, in addition to degrading dietary sources of oxalate, *Oxalobacter* may be able to derive oxalate from systemic sources by initiating or enhancing active secretion of endogenous oxalate (67). Subsequently, using various approaches, we were able to demonstrate

that *O. formigenes* can modulate intestinal oxalate transport by inducing colonic oxalate secretion (67) and a positive consequence of this bacterial-host cell interaction is a significant reduction in urinary oxalate excretion due to this enteric oxalate shunt (67). The latter study was also the first to demonstrate that endogenously derived oxalate can sustain *Oxalobacter* colonization. In the next few years, it is anticipated that there will be advances in our understanding of the mechanistic basis for bacterial cell modulation of intestinal oxalate handling since this is fundamental to future efforts in identifying which strains of bacteria and/or bacterial products will be effective in the treatment of hyperoxaluria and calcium oxalate stone disease.

An interesting addendum to this section concerns very recent communications (69,70) showing that a highly specific oxalate-degrading enzyme, formulated as cross-linked enzyme crystals (ALTU-237) significantly reduces hyperoxaluria in a knockout mouse model simulating Primary Hyperoxaluria, type 1. ALTU-237, administered orally for a month at a dose of 80 mg per day, reduced urinary oxalate by 50% and there was a total prevention of nephrocalcinosis, renal failure and death compared to the controls (70). While the enzyme was not identified in these studies for proprietary reasons, the efficacy of ALTU-237 in an animal model is impressive and underscores the potential for novel formulations of oxalate-degrading enzymes.

Studies in Humans

Based upon the results of several studies in humans, it now appears reasonable to consider the lack of intestinal *Oxalobacter* activity as a risk factor for hyperoxaluria and stones but not necessarily as a direct cause of stone disease (66,71–76). In fact, other intestinal oxalate-degrading bacteria may be important in this regard also but, as yet, there is no correlative data available for these other known/unknown microorganisms. Several studies have demonstrated that stone forming patients who lack *Oxalobacter* have significantly higher urinary oxalate excretion compared to patients colonized with the bacteria (71–74). Additional support for the notion that *Oxalobacter* may confer some protection against stone disease was suggested by other studies (66,75,76) showing a positive correlation between the number of stone episodes and the lack of intestinal *Oxalobacter* activity. More importantly, perhaps, is the concept that supplemental supplies of the oxalate-degrading bacteria or their enzyme products can potentially be used as a treatment to reduce hyperoxaluria and stone disease. In 2002, it was shown for the first time that urinary oxalate was reduced following the administration of a single oral dose of *O. formigenes* in four human subjects ingesting an oxalate load (77). More recently, oral administration of *Oxalobacter* was tested in a clinical setting involving several groups of Primary Hyperoxaluria patients (65,78–80). The patients were treated with two forms of *O. formigenes*, either a frozen cell paste or enteric-coated capsules containing the bacteria, and significant reductions in urinary oxalate were observed during treatment. Other positive outcomes, in some but not in all of these patients, included reductions in plasma oxalate concentrations and amelioration in the clinical signs of systemic oxalosis. The results of these human studies are consistent with the animal studies in that *Oxalobacter* can degrade intraluminal, dietary-derived oxalate available in the intestinal lumen, thereby reducing its absorption. Clearly, the results of these studies are encouraging and support the concept that supplemental supplies of oxalate-degrading bacteria or their enzyme products can potentially be used as a treatment to reduce hyperoxaluria. However, more clinical studies and trials are warranted and future developments in this field must include rigorous double-blind, placebo-controlled trials using probiotics/bacterial products/oxalate-degrading enzymes along with a significant contribution from basic science addressing the mechanism of action.

References

1. Finlayson, B. Some Physical and Clinical Aspects. In: David, DS., editor. *Calcium Metabolism in Renal Failure and Nephrolithiasis*. New York: John Wiley & Sons; 1977. p. 337
2. Williams, HE.; Smith, LH. Primary Hyperoxaluria. In: Stanbury, JB., et al., editors. *The Metabolic Basis of Inherited Disease*. New York: McGraw-Hill; 1983. p. 204-228.
3. Costello JF, Smith M, Stolarski C, et al. Extrarenal clearance of oxalate increases with progression of renal failure in the rat. *J Am Soc Nephrol* 1992;3(5):1098–1104. [PubMed: 1482750]
4. Hatch M, Freel RW, Vaziri ND. Intestinal excretion of oxalate in chronic renal failure. *J Am Soc Nephrol* 1994;5(6):1339–1343. [PubMed: 7893999]
5. Ito H, Kotake T, Masai M. In vitro degradation of oxalic acid by human feces. *Int J Urol* 1996;3(3):207–211. [PubMed: 8776619]
6. Hokama S, Honma Y, Toma C, et al. Oxalate-degrading *Enterococcus faecalis*. *Microbiol Immunol* 2000;44(4):235–240. [PubMed: 10832966]
7. Campieri C, Campieri M, Bertuzzi V, et al. Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. *Kidney Int* 2001;60(3):1097–1105. [PubMed: 11532105]
8. Lieske JC, Goldfarb DS, De Simone C, et al. Use of a probiotic to decrease enteric hyperoxaluria. *Kidney Int* 2005;68(3):1244–1249. [PubMed: 16105057]
9. Allison MJ, Dawson KA, Mayberry WR, et al. *Oxalobacter formigenes* gen. nov., sp. nov.: oxalate-degrading anaerobes that inhabit the gastrointestinal tract. *Arch Microbiol* 1985;141(1):1–7. [PubMed: 3994481]
10. Hatch M, Freel RW. Intestinal transport of an obdurate anion: oxalate. *Urol Res* 2005;33(1):1–16. [PubMed: 15565438]
11. Hokama S, Toma C, Iwanaga M, et al. Oxalate-degrading *Providencia rettgeri* isolated from human stools. *Int J Urol* 2005;12(6):533–538. [PubMed: 15985073]
12. Hatch, M.; Freel, RW. Oxalate transport across intestinal and renal epithelia. In: Khan, SR., editor. *Calcium Oxalate in Biological Systems*. Boca Raton: CRC Press; 1995. p. 217-238.
13. Holmes RP, Assimios DG. The impact of dietary oxalate on kidney stone formation. *Urol Res* 2004;32(5):311–316. [PubMed: 15221245]
14. Hatch M, Freel RW. Alterations in intestinal transport of oxalate in disease states. *Scanning Microsc* 1995;9(4):1121–1126. [PubMed: 8819893]discussion 1126
15. Verkoelen CF, Romijn JC. Oxalate transport and calcium oxalate renal stone disease. *Urol Res* 1996;24(4):183–191. [PubMed: 8873376]
16. Aronson PS. Essential roles of CFEX-mediated Cl(-)-oxalate exchange in proximal tubule NaCl transport and prevention of urolithiasis. *Kidney Int* 2006;70(7):1207–1213. [PubMed: 16883319]
17. Binder HJ. Intestinal oxalate absorption. *Gastroenterology* 1974;67(3):441–446. [PubMed: 4852527]
18. Freel RW, Hatch M, Earnest DL, et al. Oxalate transport across the isolated rat colon. A reexamination. *Biochim Biophys Acta* 1980;600(3):838–843. [PubMed: 7407147]
19. Dobbins JW, Binder HJ. Importance of the colon in enteric hyperoxaluria. *N Engl J Med* 1977;296(6):298–301. [PubMed: 831127]
20. Earnest DL. Enteric hyperoxaluria. *Adv. Internal Med* 1974;24:407–427. [PubMed: 371365]
21. Dobbins JW, Binder HJ. Effect of bile salts and fatty acids on the colonic absorption of oxalate. *Gastroenterology* 1976;70(6):1096–1110. [PubMed: 1269869]
22. Kathalia SC, Favus MJ, Coe FL. Evidence for size and charge permselectivity of rat ascending colon. Effects of ricinoleate and bile salts on oxalic acid and neutral sugar transport. *J Clin Invest* 1984;74(3):805–811. [PubMed: 6432849]
23. Hatch M, Freel RW, Goldner AM, et al. Comparison of effects of low concentrations of ricinoleate and taurochenodeoxycholate on colonic oxalate and chloride absorption. *Gastroenterology* 1983;84:1181.
24. Hatch, M.; Freel, RW.; Goldner, AM., et al. Effect of bile salt on active oxalate transport in the colon. In: Kasper, H.; Goebell, H., et al., editors. *Colon and Nutrition*. Lancaster, Boston: The Hague MTP Press; 1981. p. 299-303.

25. Fairclough PD, Feest TG, Chadwick VS, et al. Effect of sodium chenodeoxycholate on oxalate absorption from the excluded human colon--a mechanism for 'enteric' hyperoxaluria. *Gut* 1977;18(3):240–244. [PubMed: 852753]
26. Freel RW, Hatch M, Earnest DL, et al. Role of tight-junctional pathways in bile salt-induced increases in colonic permeability. *Am J Physiol* 1983;245(6):G816–G823. [PubMed: 6419625]
27. Hatch M, Freel RW, Goldner AM, et al. Oxalate and chloride absorption by the rabbit colon: sensitivity to metabolic and anion transport inhibitors. *Gut* 1984;25(3):232–237. [PubMed: 6698438]
28. Knickelbein RG, Aronson PS, Dobbins JW. Oxalate transport by anion exchange across rabbit ileal brush border. *J Clin Invest* 1986;77(1):170–175. [PubMed: 3003149]
29. Knickelbein RG, Aronson PS, Dobbins JW. Substrate and inhibitor specificity of anion exchangers on the brush border membrane of rabbit ileum. *J Membr Biol* 1985;88(2):199–204. [PubMed: 3005584]
30. Hatch M, Freel RW, Vaziri ND. Mechanisms of oxalate absorption and secretion across the rabbit distal colon. *Pflügers Arch* 1994;426(1–2):101–109.
31. Hatch M, Freel RW, Vaziri ND. Characteristics of the transport of oxalate and other ions across rabbit proximal colon. *Pflügers Arch* 1993;423(3–4):206–212.
32. Freel RW, Hatch M, Green M, et al. Ileal oxalate absorption and urinary oxalate excretion are enhanced in Slc26a6 null mice. *Am J Physiol Gastrointest Liver Physiol* 2006;290(4):G719–G728. [PubMed: 16373425]
33. Jiang Z, Asplin JR, Evan AP, et al. Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6. *Nat Genet* 2006;38(4):474–478. [PubMed: 16532010]
34. Freel RW, Hatch M, Vaziri ND. Conductive pathways for chloride and oxalate in rabbit ileal brush-border membrane vesicles. *Am J Physiol* 1998;275(3 Pt 1):C748–C757. [PubMed: 9730958]
35. Romero MF, Chang MH, Plata C, et al. Physiology of electrogenic SLC26 paralogues. *Novartis Found Symp* 2006;273:126–138. [PubMed: 17120765]discussion 138–147, 261–124
36. Shcheynikov N, Ko SB, Zeng W, et al. Regulatory interaction between CFTR and the SLC26 transporters. *Novartis Found Symp* 2006;273:177–186. [PubMed: 17120768]discussion 186–192, 261–174
37. Alper SL, Stewart AK, Chernova MN, et al. Anion exchangers in flux: functional differences between human and mouse SLC26A6 polypeptides. *Novartis Found Symp* 2006;273:107–119. [PubMed: 17120764]discussion 119–125, 261–104
38. Mount DB, Romero MF. The SLC26 gene family of multifunctional anion exchangers. *Pflügers Arch* 2004;447(5):710–721.
39. Soleimani M. Expression, regulation and the role of SLC26 Cl⁻/HCO₃⁻ exchangers in kidney and gastrointestinal tract. *Novartis Found Symp* 2006;273:91–102. [PubMed: 17120763]discussion 103–106, 261–104
40. Soleimani M, Xu J. SLC26 Chloride/Base Exchangers in the Kidney in Health and Disease. *Seminars in nephrology* 2006;26(5):375–385. [PubMed: 17071331]
41. Regeer RR, Lee A, Markovich D. Characterization of the human sulfate anion transporter (hsat-1) protein and gene (SAT1; SLC26A1). *DNA Cell Biol* 2003;22(2):107–117. [PubMed: 12713736]
42. Hatch M, Green ML, Freel RW. Oxalate Transport: Intestine. *NIH Oxalosis and Hyperoxaluria Workshop*. 2003
43. Karniski LP, Lotscher M, Fucentese M, et al. Immunolocalization of sat-1 sulfate/oxalate/bicarbonate anion exchanger in the rat kidney. *Am J Physiol* 1998;275(1 Pt 2):F79–F87. [PubMed: 9689008]
44. Haila S, Saarialho-Kere U, Karjalainen-Lindsberg ML, et al. The congenital chloride diarrhea gene is expressed in seminal vesicle, sweat gland, inflammatory colon epithelium, and in some dysplastic colon cells. *Histochem Cell Biol* 2000;113(4):279–286. [PubMed: 10857479]
45. Morozumi, M.; Green, M.; Freel, RW., et al. The effect of oxalate loading or acidified media on the expression of mRNA encoding candidate oxalate transporters in Caco-2 monolayers. In: Gohel, MDI.; Au, DWT., et al., editors. *Kidney Stones: Inside & Out*. Hong Kong: 2004. p. 170–180.
46. Wang Z, Wang T, Petrovic S, et al. Renal and intestinal transport defects in Slc26a6-null mice. *Am J Physiol Cell Physiol* 2005;288(4):C957–C965. [PubMed: 15574486]

47. Barmeyer C, Ye JH, Sidani S, et al. Characteristics of rat downregulated in adenoma (rDRA) expressed in HEK 293 cells. *Pflügers Arch* 2007;454(3):441–450.
48. Simpson JE, Schweinfest CW, Shull GE, et al. PAT-1 (Slc26a6) is the predominant apical membrane Cl⁻/HCO₃⁻ exchanger in the upper villous epithelium of the murine duodenum. *Am J Physiol Gastrointest Liver Physiol* 2007;292(4):G1079–G1088. [PubMed: 17170027]
49. Wang Z, Petrovic S, Mann E, et al. Identification of an apical Cl⁻/HCO₃⁻ exchanger in the small intestine. *Am J Physiol Gastrointest Liver Physiol* 2002;282(3):C573–C579.
50. Schweinfest CW, Spyropoulos DD, Henderson KW, et al. slc26a3 (dra)-deficient mice display chloride-losing diarrhea, enhanced colonic proliferation, and distinct up-regulation of ion transporters in the colon. *J Biol Chem* 2006;281(49):37962–37971. [PubMed: 17001077]
51. Silberg DG, Wang W, Moseley RH, et al. The Down regulated in Adenoma (dra) gene encodes an intestine-specific membrane sulfate transport protein. *J Biol Chem* 1995;270(20):11897–11902. [PubMed: 7744840]
52. Hatch M, Freel RW, Vaziri ND. Regulatory aspects of oxalate secretion in enteric oxalate elimination. *J Am Soc Nephrol* 1999;10:S324–S328. [PubMed: 10541256]
53. Hatch M, Freel RW. Angiotensin II involvement in adaptive enteric oxalate excretion in rats with chronic renal failure induced by hyperoxaluria. *Urol Res* 2003;31(6):426–432. [PubMed: 14574528]
54. Hatch M, Freel RW. Renal and intestinal handling of oxalate following oxalate loading in rats. *Am J Nephrol* 2003;23(1):18–26. [PubMed: 12373077]
55. Alvarez BV, Vilas GL, Casey JR. Metabolon disruption: a mechanism that regulates bicarbonate transport. *Embo J* 2005;24(14):2499–2511. [PubMed: 15990874]
56. Hassan HA, Mentone S, Karniski LP, et al. Regulation of anion exchanger Slc26a6 by protein kinase C. *Am J Physiol Cell Physiol* 2007;292(4):C1485–C1492. [PubMed: 17151144]
57. Ko SB, Zeng W, Dorwart MR, et al. Gating of CFTR by the STAS domain of SLC26 transporters. *Nat Cell Biol* 2004;6(4):343–350. [PubMed: 15048129]
58. Hegyi P, Rakonczay Z Jr, Tiszlavicz L, et al. SLC26 transporters and the inhibitory control of pancreatic ductal bicarbonate secretion. *Novartis Found Symp* 2006;273:164–173. [PubMed: 17120767]discussion 173–166, 261–164
59. Chernova MN, Jiang L, Shmukler BE, et al. Acute regulation of the SLC26A3 congenital chloride diarrhoea anion exchanger (DRA) expressed in *Xenopus* oocytes. *J Physiol* 2003;549(Pt 1):3–19. [PubMed: 12651923]
60. Greeley T, Shumaker H, Wang Z, et al. Downregulated in adenoma and putative anion transporter are regulated by CFTR in cultured pancreatic duct cells. *Am J Physiol Gastrointest Liver Physiol* 2001;281(5):G1301–G1308. [PubMed: 11668039]
61. Ko SB, Shcheynikov N, Choi JY, et al. A molecular mechanism for aberrant CFTR-dependent HCO₃⁻ transport in cystic fibrosis. *Embo J* 2002;21(21):5662–5672. [PubMed: 12411484]
62. Hoglund P. SLC26A3 and congenital chloride diarrhoea. *Novartis Found Symp* 2006;273:74–86. [PubMed: 17120762]discussion 86–90, 261–264
63. Allison, MJ.; Daniel, SL.; Cornick, NA. Oxalate-degrading bacteria. In: Khan, SR., editor. *Calcium Oxalate in Biological Systems*. Boca Raton: CRC Press; 1995. p. 131–168.
64. Goldfarb DS. Microorganisms and calcium oxalate stone disease. *Nephron Physiol* 2004;98(2):48–54.
65. Hoppe B, von Unruh G, Laube N, et al. Oxalate degrading bacteria: new treatment option for patients with primary and secondary hyperoxaluria? *Urol Res* 2005;33(5):372–375. [PubMed: 16284877]
66. Sidhu H, Schmidt ME, Cornelius JG, et al. Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium *Oxalobacter formigenes*: possible prevention by gut recolonization or enzyme replacement therapy. *J Am Soc Nephrol* 1999;10:S334–S340. [PubMed: 10541258]
67. Hatch M, Cornelius J, Allison M, et al. *Oxalobacter* sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion. *Kidney Int* 2006;69(4):691–698. [PubMed: 16518326]
68. Sidhu H, Allison MJ, Chow JM, et al. Rapid reversal of hyperoxaluria in a rat model after probiotic administration of *Oxalobacter formigenes*. *J Urol* 2001;166(4):1487–1491. [PubMed: 11547118]

69. Grujic D, Salido EC, Cachero TG, et al. Oral therapy with crystalline formulation of oxalate degrading enzyme in rodent models with hyperoxaluria. *J Urol* 2007;177(4):543.
70. Shenoy, BC.; Grujic, D.; Salido, EC., et al. The 8th International Workshop on Primary Hyperoxaluria. of Conference. London: Efficacy of an oral crystalline enzyme in a mouse genetic model for Primary Hyperoxaluria. Year
71. Neuhaus TJ, Belzer T, Blau N, et al. Urinary oxalate excretion in urolithiasis and nephrocalcinosis. *Arch Dis Child* 2000;82(4):322–326. [PubMed: 10735843]
72. Troxel SA, Sidhu H, Kaul P, et al. Intestinal *Oxalobacter formigenes* colonization in calcium oxalate stone formers and its relation to urinary oxalate. *J Endourol* 2003;17(3):173–176. [PubMed: 12803990]
73. Kwak C, Kim HK, Kim EC, et al. Urinary oxalate levels and the enteric bacterium *Oxalobacter formigenes* in patients with calcium oxalate urolithiasis. *Eur Urol* 2003;44(4):475–481. [PubMed: 14499684]
74. Mikami K, Akakura K, Takei K, et al. Association of absence of intestinal oxalate degrading bacteria with urinary calcium oxalate stone formation. *Int J Urol* 2003;10(6):293–296. [PubMed: 12757596]
75. Kumar R, Mukherjee M, Bhandari M, et al. Role of *Oxalobacter formigenes* in calcium oxalate stone disease: a study from North India. *Eur Urol* 2002;41(3):318–322. [PubMed: 12180235]
76. Mittal RD, Kumar R, Mittal B, et al. Stone composition, metabolic profile and the presence of the gut-inhabiting bacterium *Oxalobacter formigenes* as risk factors for renal stone formation. *Med Princ Pract* 2003;12(4):208–213. [PubMed: 12966191]
77. Duncan SH, Richardson AJ, Kaul P, et al. *Oxalobacter formigenes* and its potential role in human health. *Appl Environ Microbiol* 2002;68(8):3841–3847. [PubMed: 12147479]
78. Hoppe B, Beck B, Gatter N, et al. *Oxalobacter formigenes*: a potential tool for the treatment of primary hyperoxaluria type 1. *Kidney Int* 2006;70(7):1305–1311. [PubMed: 16850020]
79. Hoppe B, Hesse A, von Unruh G, et al. Treatment with *Oxalobacter formigenes*: a new therapy in patients with primary hyperoxaluria (PH)? *Pediatr Nephrol* 2003;18C15 (012)
80. Hoppe B, Gatter N, Beck B, et al. Oral administration of *Oxalobacter formigenes* capsules is effective in lowering the urinary oxalate excretion in patients with primary hyperoxaluria type 1 (PH I). *J Am Soc Nephrol* 2004;15SU-FC056, P055A